Show simple item record

dc.contributor.authorWilliams, R.
dc.contributor.authorMamotte, Cyril
dc.contributor.authorBurnett, J.
dc.date.accessioned2017-01-30T15:12:29Z
dc.date.available2017-01-30T15:12:29Z
dc.date.created2009-03-05T00:55:47Z
dc.date.issued2008
dc.identifier.citationWilliams, Robin A. and Mamotte, Cyril D. S. and Burnett, John R. 2008. Phenylketonuria: An Inborn Error of Phenylalanine Metabolism. The Clinical Biochemist Reviews 29: pp. 31-41.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/44157
dc.description.abstract

Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine (Phe) metabolism resulting from deficiency of phenylalanine hydroxylase (PAH). Most forms of PKU and hyperphenylalaninaemia (HPA) are caused by mutations in the PAH gene on chromosome 12q23.2. Untreated PKU is associated with an abnormal phenotype which includes growth failure, poor skin pigmentation, microcephaly, seizures, global developmental delay and severe intellectual impairment. However, since the introduction of newborn screening programs and with early dietary intervention, children born with PKU can now expect to lead relatively normal lives. A better understanding of the biochemistry, genetics and molecular basis of PKU, as well as the need for improved treatment options, has led to the development of new therapeutic strategies.

dc.publisherThe Australasian Association of Clinical Biochemists Inc.
dc.titlePhenylketonuria: An Inborn Error of Phenylalanine Metabolism
dc.typeJournal Article
dcterms.source.volume29
dcterms.source.startPage31
dcterms.source.endPage41
dcterms.source.titleThe Clinical Biochemist Reviews
dcterms.source.isbn0159 - 8090
curtin.accessStatusFulltext not available
curtin.facultyFaculty of Health Sciences
curtin.facultySchool of Biomedical Sciences


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record